BioWorld

Tempus wins breakthrough status for AI-based tool to detect atrial fibrillation

Mar 24, 2021

Cardiology

Clinical Trials

Media Coverage

Related content

Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-AF, an AI-based Algorithm that Identifies Patients at Increased Risk of AFib

Tempus Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension

Tempus Announces Participation in National Cancer Institute’s ComboMATCH Trials

Clinical Trials